Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Goyang, Korea.
Radiation Oncology, Center for Pediatric Cancer, National Cancer Center, Goyang, Korea.
J Cancer Res Clin Oncol. 2023 Jul;149(7):3109-3119. doi: 10.1007/s00432-022-04192-x. Epub 2022 Jul 23.
This study aimed to analyze characteristics, treatment, long-term outcomes, and prognostic factors for children, adolescents and young adults with rhabdomysosarcoma (RMS).
This retrospective historical study included 75 patients with RMS treated between 2002 and 2019. Clinical data and follow-up results were collected including all diagnosis, treatment and prognosis information.
Patients median-age-at-diagnosis was 6 years. Embryonal and alveolar histology occurred in 51 (68.0%) and 21 (28.0%) patients, respectively. The tumors most frequently originated from parameningeal site (28.0%). Of 74 evaluable patients for treatment outcome, 60 (81.1%) achieved complete response for first-line treatment, of whom, 34 (56.6%) maintained complete response, 26 (43.3%; 23/26, local relapse) showed relapse. Of 40 patients with treatment failure, 16 and 6 occurred in parameningeal area and retroperitoneum/perineum, respectively. The 5-year progression-free survival (PFS) and overall survival (OS) were 45.0% and 64.5%, respectively. In multivariate analyses, parameningeal site (p = 0.027), no gross total resection (p = 0.047), and no radiation therapy (RT) (p < 0.001) for PFS; and parameningeal site (p < 0.001) and no RT (p = 0.010) for worse OS, were significant. The median PFS and OS from treatment failure date in 40 patients with primary treatment failure were 1.3 and 4.1 years, respectively. Of 26 patients with relapse, interval to relapse < 7 months, retroperitoneum/perineum site, TNM stages III/IIV, and no salvage RT were independently associated with OS.
The importance of adequate local therapy was highlighted in RMS treatment. Treatment failure was largely a local failure. Whether as a component of initial or salvage treatment, RT could improve patients' survival.
本研究旨在分析儿童、青少年和年轻成人横纹肌肉瘤(RMS)的特征、治疗方法、长期结果和预后因素。
这是一项回顾性历史研究,纳入了 2002 年至 2019 年间接受治疗的 75 例 RMS 患者。收集了所有诊断、治疗和预后信息的临床数据和随访结果。
患者中位诊断年龄为 6 岁。胚胎型和肺泡型组织学分别占 51(68.0%)和 21(28.0%)例。肿瘤最常起源于脑脊膜旁部位(28.0%)。74 例可评估治疗结果的患者中,60(81.1%)例一线治疗完全缓解,其中 34(56.6%)例持续完全缓解,26(43.3%;23/26,局部复发)例复发。40 例治疗失败的患者中,16 例和 6 例分别发生在脑脊膜旁区和腹膜后/会阴区。5 年无进展生存率(PFS)和总生存率(OS)分别为 45.0%和 64.5%。多因素分析显示,脑脊膜旁部位(p=0.027)、未完全切除(p=0.047)和未行放疗(RT)(p<0.001)与 PFS 相关;脑脊膜旁部位(p<0.001)和未行 RT(p=0.010)与 OS 较差相关。40 例原发性治疗失败患者的中位 PFS 和 OS 分别为 1.3 年和 4.1 年。26 例复发患者中,复发间隔<7 个月、腹膜后/会阴部位、TNM 分期 III/IV 期和无挽救性 RT 与 OS 独立相关。
本研究强调了充分的局部治疗在 RMS 治疗中的重要性。治疗失败主要是局部失败。放疗无论是作为初始治疗还是挽救性治疗的一部分,都可以改善患者的生存。